ArticleOncotarget2017

The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.

Annarita Scialdone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.